Stimate (desmopressin acetate) was a nasal spray developed to control bleeding in people with mild hemophilia A that has been recalled and currently is unavailable. The product was sold under the brand name Octim in Europe and Octostim in Canada.
Search results for:
Decades ago most hemophilia patients died young. Advances in treatment have led to them living about as long as the general population, which means that for the first time, doctors are facing the challenge of caring for aging hemophiliacs. A key problem is that in the days before treatment breakthroughs,…
I have fond memories of my dad sitting at the kitchen table on Sunday mornings. After attending church, he read the newspaper while the radio played his favorite Tejano music. He always read articles to my mom as they sat together, enjoying the morning. The crisp newspaper would buckle as…
What happens when a symptomatic hemophilia carrier needs minor surgery? Will her increased risk of bleeding be recognized? The story of Kim H. came to my attention on Facebook. She is 39 years old and lives in Pennsylvania. I recently interviewed Kim over Zoom, as her story is important.
Life can change in a moment. Sometimes, all it takes is a phone call — that a loved one has passed away, that you’ve lost your job, or that you are free from cancer. Those moments often create core memories — highly emotional, significant experiences that have a lasting…
In this series of podcasts from Bloodstream Media and shared by Bloodfeed, host Patrick James Lynch submits questions about hemophilia and other bleeding disorders from listeners to various hemophilia and health care experts. MORE:Â The Hemophilia CHOICE Project Survey The podcasts feature a pediatric hematologist, Dr. Arash…
Four years ago, I relocated to a rural community. My hemophilia treatment center (HTC) was six hours away, so I met with a local hematologist to come up with a plan for treatment. I am a woman. I was speaking to a female physician who specialized…
Refixia or Rebinyn (nonacog beta pegol, or N9-GP), an approved replacement therapy for hemophilia B, is effective and has a good safety profile in previously untreated boys younger than 6 with severe to moderately severe disease, an early analysis of a Phase 3 trial indicates. In…
Last in a series. Read parts one and two. Guinea pigs are similar to humans. Their body chemistry has led to testing that’s revolutionized research, with the development of vaccines, replacement heart valves, and asthma medications, to name a few. The term “guinea pig” has become synonymous with…
ASC Therapeutics has joined forces with Charles River to scale the manufacturing of ASC618, its second-generation virus-based gene therapy for hemophilia A. The agreement expands upon their current collaboration, begun in 2019 that focused on achieving Good Manufacturing Practice (GMP)-virus manufacturing and establishing processes for adeno-associated virus (AAV) production…